Beijing BIOOCUS Biotech Ltd. is proud to introduce Abecma, the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma. Abecma, also known as idecabtagene vicleucel, is a groundbreaking therapy that uses the patient's own immune cells to target and kill cancer cells. This personalized approach has shown remarkable results in clinical trials, with a significant number of patients experiencing remission and prolonged survival, With a commitment to excellence and a focus on improving patient outcomes, we are dedicated to advancing the field of cell-based therapies and revolutionizing the way we treat cancer. We are confident that Abecma will have a profound impact on the lives of patients and their families, and we are excited to be at the forefront of this groundbreaking advancement in cancer treatment
Please feel free to give your inquiry in the form below We will reply you in 24 hours